Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in patients living with relapsing multiple sclerosis (MS ...

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Roche announced that the phase III MUSETTE trial comparing a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Early treatment with Ocrevus may help protect the cerebellum from damage in people with multiple sclerosis, a study found.

At the American Academy of Neurology (AAN) 2025 Annual Meeting Contemporary Clinical Issues Plenary Session, held in San Diego, California, from 5 April to 9 April 2025, Genentech presented data ...

Ocrevus is competing in a crowded market for MS drugs, but looks likely to have advantages over already marketed rivals. Along with strong efficacy figures in relapsing disease, trial evidence ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

The usual Ocrevus dosage for multiple sclerosis (MS) and clinically isolated syndrome is two starting infusions given 2 weeks apart, and then an infusion every 6 months. Ocrevus (ocrelizumab ...